RECRUITING

Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients

Conditions

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Einstein Medical Center in Philadelphia serves a diverse group of the patient population. The majority of patients have a diverse cultural background, low literacy, and poor social-economic status. Medication adherence for chronic medical problems is in a range of 40-70%. Medication adherence among patients on oral anti-cancer therapy is not studied in detail. The main objective is to study medication adherence to oral anticancer agents in patients with low literacy and poor socio-economic status.

Official Title

A Randomized, Controlled Trial to Assess Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients in a Socioeconomically Disadvantaged Community

Quick Facts

Study Start:2017-07-20
Study Completion:2025-12-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03245411

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients on oral chemotherapeutic agents
  2. * Clinical diagnosis of stage IV breast cancer
  3. * Clinical diagnosis of stage III and IV colorectal cancer (not receiving concurrent radiation therapy)
  4. * Clinical diagnosis of stage IV non-small cell lung cancer
  5. * Clinical diagnosis of stage IV renal cell carcinoma
  6. * Clinical diagnosis of stage IV ovarian carcinoma
  7. * Clinical diagnosis of multiple myeloma
  8. * Clinical diagnosis of chronic myelogenous leukemia on TKI
  9. * Clinical diagnosis of myelodysplastic syndrome on Lenalidomide
  10. * Adjuvant treatment for Gastro Intestinal Stromal Tumor
  11. * Clinical diagnosis of chronic Lymphocytic Leukemia
  12. * Clinical diagnosis of metastatic Prostate cancer
  13. * Clinical diagnosis of hepatocellular Carcinoma
  14. * Clinical diagnosis of stage IV Melanoma
  15. * Clinical diagnosis of myelofibrosis/myeloproliferative neoplasms
  16. * Age \>18 years
  17. * ECOG Performance Status \<3
  1. * ECOG Performance Status of 3 and above
  2. * Concurrent chemo radiation
  3. * Non-English speaker
  4. * Clinical diagnosis of dementia, or otherwise unable to give informed consent.
  5. * History of non-compliance (defined as the history of 2 or more missed appointments in the clinic).
  6. * Pregnant patients
  7. * Nursing Home Patients
  8. * Incarcerated

Contacts and Locations

Study Contact

Claudia M Dourado, MD
CONTACT
215-456-3880
Douradoc@einstein.edu
Claudia Dourado
CONTACT
215-456-3880
Douradoc@einstein.edu

Principal Investigator

Claudia M Dourado, MD
PRINCIPAL_INVESTIGATOR
Thomas Jefferson University

Study Locations (Sites)

Albert Einstein Healthcare Network
Philadelphia, Pennsylvania, 19141
United States

Collaborators and Investigators

Sponsor: Thomas Jefferson University

  • Claudia M Dourado, MD, PRINCIPAL_INVESTIGATOR, Thomas Jefferson University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-07-20
Study Completion Date2025-12-20

Study Record Updates

Study Start Date2017-07-20
Study Completion Date2025-12-20

Terms related to this study

Additional Relevant MeSH Terms

  • Cancer